ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.86 EUR | +0.77% |
|
-0.16% | -10.21% |
| 06-02 | Astra's Enhertu breast cancer trial shows 'unprecedented' results | RE |
| 06-02 | Astra's Enhertu delays breast cancer in patients with low HER2 levels | RE |
| Sales 2024 * | 60.36B 66.94B 61.68B 91.2B | Sales 2025 * | 63.82B 70.77B 65.21B 96.42B | Capitalization | 186B 207B 191B 282B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.27B 14.72B 13.56B 20.05B | Net income 2025 * | 14.76B 16.37B 15.08B 22.3B | EV / Sales 2024 * | 3.32 x |
| Net Debt 2024 * | 13.79B 15.29B 14.09B 20.83B | Net Debt 2025 * | 7.91B 8.77B 8.08B 11.95B | EV / Sales 2025 * | 3.05 x |
| P/E ratio 2024 * |
13.6
x | P/E ratio 2025 * |
12.3
x | Employees | 103,605 |
| Yield 2024 * |
4.24% | Yield 2025 * |
4.36% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
| 1 day | +0.77% | ||
| 1 week | -0.16% | ||
| 1 month | +3.44% | ||
| 3 months | -4.50% | ||
| 6 months | -7.47% | ||
| Current year | -10.21% |
1 week
28.64
29.00
1 month
27.4930.74
Current year
27.1034.50
1 year
27.1038.40
3 years
27.1049.48
5 years
27.1049.48
10 years
22.2049.48
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 95-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 28.86 | +0.77% | 0 |
| 24-05-30 | 28.64 | -0.38% | 0 |
| 24-05-29 | 28.75 | -0.86% | 0 |
| 24-05-28 | 29 | -0.68% | 50 |
| 24-05-27 | 29.2 | +1.02% | 7 |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 02:14 am
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231
CHF
Average target price
277.5
CHF
Spread / Average Target
+20.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- ROG Stock
- RHO6 Stock
